Key takeaways
Harvoni (ledipasvir/sofosbuvir) and Olysio (simeprevir) are both antiviral medications used to treat hepatitis C. However, they differ in several ways. Harvoni is a combination medication that includes two antiviral agents, ledipasvir and sofosbuvir, and is FDA-approved for treating hepatitis C genotypes 1, 4, 5, and 6. It is taken as a single tablet once a day and is available in both brand and generic forms. In contrast, Olysio (simeprevir) was used in combination with peginterferon and ribavirin, which are known for having many side effects, and it has been discontinued due to the availability of newer, more effective treatments. Harvoni is known for its high cure rates and fewer side effects, such as headache and fatigue, while Olysio required additional medications that could cause more severe side effects. Additionally, Harvoni interacts with several medications, including heartburn medications and some HIV antiretrovirals, whereas Olysio's interactions were primarily related to its combination with peginterferon and ribavirin.
